Average Daily Volume
194.7K
Fund Overview
The iShares Global Healthcare ETF (IXJ) seeks to track the investment results of the S&P Global 1200 Healthcare Sector Index, which measures the performance of companies in the healthcare sector globally. The fund provides exposure to large, mid, and small-cap healthcare companies across developed and emerging markets, including pharmaceuticals, biotechnology, medical devices, and healthcare services. IXJ offers investors a convenient way to gain diversified access to the global healthcare industry, which is known for its defensive characteristics and long-term growth potential driven by demographic trends and innovation. The ETF is designed for investors seeking broad healthcare exposure with the liquidity and transparency of an exchange-traded fund.
- Asset Class
-
Equity
- Industry
-
Broad Healthcare
- Annual Dividend Rate
-
- Smart Beta
-
No
- Leveraged / Inverse
-
N/A / No
- Dividend Quality - Yield
-
- 1.39 %
- Currency Hedged
-
No
- Portfolio Turnover
-
3 %
- Dividend Date
-
Why Invest in the IXJ ETF?
Potential Benefits
- Provides diversified exposure to the global healthcare sector, including pharmaceuticals, biotech, and medical devices.
- Offers defensive characteristics, as healthcare demand tends to be less sensitive to economic cycles.
- Captures long-term growth potential driven by aging populations and medical innovation.
- Liquidity and transparency of an ETF structure with low expense ratios compared to actively managed funds.
- Includes both developed and emerging market healthcare companies for broader geographic diversification.
Potential Risks
- Sector concentration risk, as the fund is entirely focused on healthcare, which may underperform other sectors.
- Regulatory risks, as healthcare companies are subject to government policies and drug approval processes.
- Biotech and pharmaceutical firms face high R&D costs and patent expiration risks.
- Currency fluctuations may impact returns for non-U.S. holdings.
- Valuation risks, as some healthcare stocks may trade at high multiples due to growth expectations.
RSI data unavailable or insufficient history.
Monthly Returns (%)
| Year |
Jan |
Feb |
Mar |
Apr |
May |
Jun |
Jul |
Aug |
Sep |
Oct |
Nov |
Dec |
| 2026 |
+1.4%
|
+3.0%
|
-8.0%
|
-0.7%
|
+1.7%
|
+5.0%
|
+1.9%
|
+4.0%
|
-2.0%
|
+10.3%
|
+2.1%
|
-
|
| 2025 |
+6.3%
|
+1.9%
|
-2.1%
|
-2.3%
|
-3.8%
|
+1.3%
|
-3.5%
|
+5.5%
|
+1.1%
|
+2.9%
|
+8.3%
|
-0.7%
|
| 2024 |
+2.4%
|
+2.4%
|
+2.4%
|
-4.1%
|
+3.0%
|
+1.6%
|
+3.2%
|
+5.6%
|
-3.1%
|
-4.9%
|
-0.9%
|
-6.4%
|
| 2023 |
-0.5%
|
-4.5%
|
+3.4%
|
+3.6%
|
-3.8%
|
+3.1%
|
+1.1%
|
-0.9%
|
-3.3%
|
-3.8%
|
+5.6%
|
+4.3%
|
| 2022 |
-6.9%
|
-0.8%
|
+5.0%
|
-4.6%
|
+1.1%
|
-3.3%
|
+3.2%
|
-6.4%
|
-3.9%
|
+8.7%
|
+5.8%
|
-1.6%
|
| 2021 |
+0.5%
|
-2.9%
|
+3.3%
|
+3.2%
|
+2.6%
|
+2.5%
|
+3.6%
|
+2.6%
|
-5.2%
|
+4.3%
|
-3.4%
|
+7.7%
|
| 2020 |
-1.5%
|
-6.9%
|
-3.3%
|
+11.3%
|
+3.5%
|
-1.2%
|
+3.7%
|
+2.4%
|
-1.6%
|
-5.0%
|
+8.9%
|
+3.5%
|
| 2019 |
+5.0%
|
+1.9%
|
+0.8%
|
-2.5%
|
-2.1%
|
+6.6%
|
-1.5%
|
+0.3%
|
+0.2%
|
+5.0%
|
+4.5%
|
+3.3%
|
| 2018 |
+5.7%
|
-4.7%
|
-1.7%
|
+0.7%
|
+0.2%
|
+1.4%
|
+6.3%
|
+2.7%
|
+2.2%
|
-6.3%
|
+5.7%
|
-8.1%
|
| 2017 |
+2.4%
|
+5.4%
|
+0.4%
|
+2.0%
|
+2.4%
|
+2.8%
|
+0.1%
|
+1.2%
|
+1.5%
|
-1.4%
|
+2.4%
|
-0.3%
|
< -5%
-5% to -2%
-2% to 0%
0%
0% to +2%
+2% to +5%
> +5%
Top Holdings (by weight)
| Symbol |
Company Name |
Weight |
|
LLY
|
ELI LILLY AND CO |
8.5 % |
|
UNH
|
UNITEDHEALTH GROUP INC |
7.5 % |
|
JNJ
|
JOHNSON & JOHNSON |
5.4 % |
|
ABBV
|
ABBVIE INC |
4.4 % |
|
ABT
|
ABBOTT LABORATORIES |
3.2 % |
|
MRK
|
MERCK & CO INC |
3.0 % |
|
ISRG
|
INTUITIVE SURGICAL INC |
2.4 % |
|
TMO
|
THERMO FISHER SCIENTIFIC INC |
2.4 % |
|
AMGN
|
AMGEN INC |
2.2 % |
|
BSX
|
BOSTON SCIENTIFIC CORP |
2.0 % |
Top 10 holdings shown, out of 114 total holdings.
Related ETFs: IXJ vs Peers
Comparison highlights key differences on cost, coverage, and focus within sector ETFs.
Investment Strategy
IXJ tracks the S&P Global 1200 Healthcare Sector Index, which includes healthcare companies from the S&P Global 1200, a broad global equity index. The index methodology uses a modified market-capitalization weighting approach, meaning larger companies generally have greater influence on performance, though some adjustments may be made for liquidity and investability. The fund holds stocks across the healthcare spectrum—pharmaceutical firms, biotech innovators, medical device manufacturers, and healthcare service providers—providing comprehensive sector exposure. The ETF is passively managed and rebalanced quarterly to align with index changes, maintaining its target allocations efficiently.
Frequently Asked Questions
What percentage of IXJ is invested in U.S. healthcare stocks?
As of the latest holdings data, approximately 60-65% of IXJ is allocated to U.S. healthcare companies, with the remainder spread across Europe, Japan, and other developed markets.
Does IXJ include exposure to emerging market healthcare companies?
Yes, while primarily focused on developed markets, IXJ does include some emerging market exposure through holdings in countries like China and India where healthcare companies meet the index's size and liquidity requirements.
How often does IXJ rebalance its holdings?
IXJ rebalances quarterly to match changes in the underlying S&P Global 1200 Healthcare Sector Index, ensuring the fund maintains accurate representation of the global healthcare market.
What is the largest holding in IXJ?
The fund's top holdings typically include global pharmaceutical giants like Johnson & Johnson, UnitedHealth Group, and Roche, though exact weightings change with market conditions and index rebalancing.
Is IXJ suitable for dividend investors?
While IXJ does provide some dividend income from established pharma companies, it's primarily a growth-oriented healthcare play rather than a high-yield dividend ETF, as many biotech and medical device holdings reinvest earnings rather than pay substantial dividends.
Industry Overview
The iShares Global Healthcare ETF (IXJ) provides exposure to the healthcare sector, a critical and growing industry worldwide. Healthcare is often considered a defensive sector due to consistent demand for medical services, pharmaceuticals, and innovative treatments. The industry benefits from long-term tailwinds such as aging populations in developed markets, rising healthcare spending in emerging economies, and advancements in biotechnology and medical technology. IXJ offers investors a way to participate in these trends while diversifying across sub-sectors (pharma, biotech, devices, services) and geographies (U.S., Europe, Asia, etc.). The ETF's global approach helps mitigate country-specific risks while capturing growth opportunities across different healthcare markets.
Alternative Comparison
Compared to U.S.-focused healthcare ETFs like XLV or VHT, IXJ offers broader geographic diversification with significant exposure to European and Asian healthcare firms. While XLV has a lower expense ratio (0.09% vs IXJ's 0.43%), IXJ's global mandate may justify the higher cost for investors seeking international healthcare exposure. Against specialized biotech ETFs like IBB or XBI, IXJ provides more balanced exposure across healthcare subsectors rather than concentrated biotech risk. Unlike some actively managed healthcare funds, IXJ's passive approach ensures consistent, rules-based exposure without manager bias.
Issuer Overview
iShares by BlackRock is the world's largest ETF provider, known for its extensive lineup of index-tracking funds across asset classes and sectors. With trillions in assets under management, iShares offers investors reliable, low-cost access to various markets through transparent ETF structures. The firm's global reach and scale contribute to tight bid-ask spreads and strong liquidity in its products like IXJ.
Conclusion
IXJ serves as a comprehensive tool for investors seeking global healthcare exposure in a single ETF. Its diversified approach across healthcare subsectors and geographies helps mitigate single-company or single-country risks while capturing the sector's long-term growth potential. While the expense ratio is higher than some U.S.-focused peers, the global diversification may warrant the additional cost for certain investors. As with any sector fund, IXJ works best as part of a diversified portfolio rather than a standalone holding.
Boost Your Returns with SectorSurfer
Award-winning investment strategy automation